OUYANG De-fang, NIE Shu-fang, MENG Jin, YANG Xing-gang, SONG Zhi-quan, PAN Wei-san*. Compound Metformin/Glipizide Bilayer Extended Release Tablets: Development and in Vitro Release[J]. .
[1] Carruthers SG, Brian BH, Kenneth LM. Clinical Pharmacology [M]. 4nd ed. Beijing : Mc Graw-Hill. 2000. 529-551. [2] Bertram GK. Basic and Clinical Pharmacology [M]. 8nd ed. Mc Graw-Hill. 2001. 711-734. [3] Enose AA, Prithiviraj A, Kesavan B, et al. Eudragit NE30D based metformin/gliclazide extended release tablets : formulation, characterisation and in vitro release studies [J]. Chem Pharm Bull, 2002, 50 (11), 1495-1498. [4] Matharu AS. Pharmaceutical Composition [P]. US Pat : 0021841, 2003-01-30. [5] Food and Drug Administration. FDA Guidance for Industry : Dissolution Testing of Immediate Release Solid Dosage Forms [M]. Rockville, MD. USA, August, 1997. [6] State Pharmacopeia Committee of the People’s Republic of China. Pharmacopeia of the People’s Republic of China [S]. 2000 ed. Beijing : Chemical Industry Press, 2000. Monographs : 703-705. [7] United States Pharmacopeial Convention, Inc. Pharmacopeia of the United States [S]. 2003 26 nd. Official Monographs. Washington : The Board of Trustees Official. 2003. 858-860. [8] Food and Drug Administration. FDA guidance for industry : waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system [M]. Rockville, MD. USA, August, 2000.